Iourov Ivan Y, Vorsanova Svetlana G, Yurov Yuri B
Mental Health Research Center, 117152 Moscow, Russia.
2Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University, Ministry of Health of Russian Federation, 125412 Moscow, Russia.
Mol Cytogenet. 2019 Feb 4;12:4. doi: 10.1186/s13039-019-0418-4. eCollection 2019.
In medical genetics, diseases are classified according to the nature (hypothetical nature) of the underlying genetic defect. The classification is "gene-centric" and "factor-centric"; a disease may be, thereby, designated as monogenic, oligogenic or polygenic/multifactorial. Chromosomal diseases/syndromes and abnormalities are generally considered apart from these designations due to distinctly different formation mechanisms and simultaneous encompassing from several to several hundreds of co-localized genes. These definitions are ubiquitously used and are perfectly suitable for human genetics issues in historical and academic perspective. However, recent achievements in systems biology have offered a possibility to explore the consequences of a genetic defect from genomic variations to molecular/cellular pathway alterations unique to a disease. Since pathogenetic mechanisms (pathways) are more influential on our understating of disease presentation and progression than genetic defects per se, a need for a disease classification reflecting both genetic causes and molecular/cellular mechanisms appears to exist. Here, we propose an extension to the common disease classification based on the underlying genetic defects, which focuses on disease-specific molecular pathways.
The basic idea of our classification is to propose pathways as parameters for designating a genetic disease. To proceed, we have followed the tradition of using ancient Greek words and prefixes to create the terms for the pathway-based classification of genetic diseases. We have chosen the word "griphos" (γρῖφος), which simultaneously means "net" and "puzzle", accurately symbolizing the term "pathway" currently used in molecular biology and medicine. Thus, diseases may be classified as monogryphic (single pathway is altered to result in a phenotype), digryphic (two pathways are altered to result in a phenotype), etc.; additionally, diseases may be designated as oligogryphic (several pathways are altered to result in a phenotype), polygryphic (numerous pathways or cascades of pathways are altered to result in a phenotype) and homeogryphic in cases of comorbid diseases resulted from shared pathway alterations. We suppose that classifying illness this way using both "gene-centric" and "pathway-centric" concepts is able to revolutionize current views on genetic diseases.
在医学遗传学中,疾病是根据潜在遗传缺陷的性质(假设性质)进行分类的。这种分类是以“基因中心”和“因素中心”为基础的;因此,一种疾病可能被指定为单基因、寡基因或多基因/多因素疾病。染色体疾病/综合征和异常通常由于形成机制明显不同且同时涉及从几个到几百个共定位基因,而与这些分类有所不同。这些定义被广泛使用,从历史和学术角度来看,非常适用于人类遗传学问题。然而,系统生物学的最新成果提供了一种可能性,即探索从基因组变异到疾病特有的分子/细胞途径改变的遗传缺陷的后果。由于致病机制(途径)对我们理解疾病表现和进展的影响比遗传缺陷本身更大,因此似乎需要一种既能反映遗传原因又能反映分子/细胞机制的疾病分类方法。在此,我们提出了一种基于潜在遗传缺陷的常见疾病分类的扩展方法,该方法侧重于疾病特异性分子途径。
我们分类的基本思想是提出途径作为指定遗传疾病的参数。为此,我们沿袭了使用古希腊词语和前缀来创建基于途径的遗传疾病分类术语的传统。我们选择了“griphos”(γρῖφος)这个词,它同时意味着“网”和“谜题”,准确地象征了目前分子生物学和医学中使用的“途径”一词。因此,疾病可以分类为单途径型(单一途径改变导致一种表型)、双途径型(两条途径改变导致一种表型)等;此外,疾病可以被指定为寡途径型(几种途径改变导致一种表型)、多途径型(许多途径或途径级联改变导致一种表型),而在由共享途径改变导致的共病情况下则为同源途径型。我们认为,以这种方式使用“基因中心”和“途径中心”概念对疾病进行分类能够彻底改变当前对遗传疾病的看法。